COCP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
105.0K
-53.3%
225.0K
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
105.0K
-53.3%
225.0K
0
0
0
Operating Expenses
3.3M
+27.4%
2.6M
+4.0%
2.5M
+18.8%
2.1M
-0.9%
2.1M
R&D
2.1M
+56.2%
1.4M
-15.3%
1.6M
+69.7%
954.0K
-15.0%
1.1M
SG&A
1.1M
-5.2%
1.2M
+40.4%
862.0K
-24.1%
1.1M
+15.1%
986.0K
Operating Income
-3184000
-35.1%
-2356000
+5.0%
-2481000
-18.8%
-2089000
+0.9%
-2108000
EBITDA
-3172000
-35.3%
-2344000
+5.0%
-2468000
-18.9%
-2076000
+0.5%
-2087000
Net Income
-3164000
-37.6%
-2299000
+5.2%
-2426000
-18.4%
-2049000
+0.3%
-2055000
EPS (Basic)
$-0.23
-35.3%
$-0.17
+5.6%
$-0.18
+5.3%
$-0.19
+5.0%
$-0.20
EPS (Diluted)
$-0.23
-35.3%
$-0.17
+5.6%
$-0.18
+5.3%
$-0.19
+5.0%
$-0.20
Shares (Diluted)
13.8M
+0.0%
13.8M
-0.3%
13.8M
+25.7%
11.0M
+8.0%
10.2M
Cocrystal Pharma (COCP) โ€” Financials